Volatile Anaesthesia and Perioperative Outcomes Related to Cancer: the VAPOR-C Trial

Last updated: March 11, 2025
Sponsor: Peter MacCallum Cancer Centre, Australia
Overall Status: Terminated

Phase

3

Condition

Rectal Cancer

Rectal Disorders

Colon Cancer

Treatment

Propofol

Sevoflurane

Lidocaine IV

Clinical Study ID

NCT04316013
18/044
  • Ages > 18
  • All Genders

Study Summary

VAPOR-C is a randomised study of the impact of IV versus inhaled anaesthesia (propofol versus sevoflurane) and lidocaine versus no lidocaine on duration of disease free survival inpatients with either colorectal or non small cell lung cancer.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Male or female patients aged 18 years or older at screening

  2. Has provided written informed consent for the trial

  3. Patient with American Joint committee on Cancer (AJCC) 8th edition Stage I-IIIcolorectal cancer or Stage I-IIIa NSCLC, as confirmed by histological or cytologicaldiagnosis. In cases where a histological diagnosis is not possible, suspecteddiagnosis through imaging techniques is acceptable.

  4. Patient has an American Society of Anaesthesiologists (ASA) score of 1 to 3

  5. Scheduled to receive elective, surgical resection with curative intent

  6. Surgery expected to last ≥2 hours and expected to require ≥2 nights hospital stay

  7. Able to comply with protocol requirements and follow-up procedures

Exclusion

Exclusion Criteria:

  1. Confirmed or suspected allergy to propofol, sevoflurane or intravenous lidocaine

  2. Patient with significant liver disease (with elevated International Normalised Ratio (INR) or bilirubin and/or low albumin; i.e. Childs-Pugh Score >Class A;

  3. Patient at personal or familial risk of malignant hyperthermia or porphyria

  4. Patient with a history of other malignancies within the past 5 years. However,patients with malignancies managed with curative therapy and considered to be at lowrisk of recurrence such as treated skin basal cell carcinoma, squamous cellcarcinoma, malignant melanoma ≤1.0mm without ulceration, localised thyroid cancer,cervical carcinoma in situ or prior malignancies with high likelihood of cure (e.g.low grade prostate and breast cancer) may be included in the study

  5. Patient has distant metastases

  6. Patient with an actual body weight less than 45kg

  7. Patients taking the following drugs that are moderate-strong inhibitors of theCYP1A2 and CYP3A4 metabolic pathways within 72 hours prior to surgery: Antibiotics - 'mycin' class: Clarithromycin, Telithromycin, Azithromycin, Erythromycin Antibiotics

  • 'floxacin' class Ciprofloxacin (exception: can be used preoperatively within abowel prep regime), Norfloxacin, Levofloxacin, Sparfloxacin Antibiotics - other:Chloramphenicol, Isoniazid Antifungals: Fluconazole, Itraconazole, Ketoconazole,Posaconazole, Voriconazole Antiretrovirals: Atazanavir; Darunavir; Indinavir;Lopinavir; Nelfinavir; Ombitasvir, Paritaprevir, Ritonavir and Saquinavir.Antidepressants/ADHD: Fluvoxamine, Enoxacine. Calcium-channel blockers: Diltiazem,Verapamil Monoclonal Antibodies: Ceritinib, Idelalisib, Lonafarnib, Tucatinib. Otherstrong cytochrome P450 3A4 inhibitors: Cimetidine, Cobicistat; grapefruit juice,Mifepristone, Nefazodone.

Study Design

Total Participants: 254
Treatment Group(s): 3
Primary Treatment: Propofol
Phase: 3
Study Start date:
July 31, 2020
Estimated Completion Date:
February 28, 2025

Study Description

VAPOR-C is a pragmatic, event-driven, randomised controlled trial, with a single blind 2x2 factorial design for sevoflurane/propofol and for intravenous lidocaine infusion / no lidocaine infusion.

This trial is designed to test for superiority in disease free survival (DFS) of propofol (total intravenous anaesthesia -TIVA) over sevoflurane (inhalational volatile anaesthesia) and intravenous lidocaine over no lidocaine in patients undergoing surgery for colorectal or non small cell lung cancer (NSCLC). The combination of two cancer types will help address the need to demonstrate the effects of anaesthetic technique across cancers to inform generalisable anaesthesia guidelines. Both NSCLC and colorectal cancer are important for this study due to high incidence rate, many longer-term survivors, and importantly the high risk of local or distant recurrence despite complete surgical resection. In addition, the study will collect additional data in a nested cohort related to the exploratory objectives.

The study aims to recruit 3,500 patients in Australia, New Zealand, Canada, United States and Europe.

Connect with a study center

  • Chris O'Brien Lifehouse

    Camperdown, New South Wales 2050
    Australia

    Site Not Available

  • Royal Prince Alfred Hospital

    Camperdown, New South Wales 2050
    Australia

    Site Not Available

  • Prince of Wales Hospital

    Randwick, New South Wales 2031
    Australia

    Site Not Available

  • Royal Brisbane and Women's Hospital

    Herston, Queensland 4029
    Australia

    Site Not Available

  • Mackay Base Hospital

    Mackay, Queensland 4740
    Australia

    Site Not Available

  • RedCliffe Hospital

    Redcliffe, Queensland 4020
    Australia

    Site Not Available

  • Rockhampton Hospital

    Rockhampton, Queensland 4700
    Australia

    Site Not Available

  • Gold Coast University Hospital

    Southport, Queensland 4215
    Australia

    Site Not Available

  • Princess Alexandra Hospital

    Woolloongabba, Queensland 4102
    Australia

    Site Not Available

  • Royal Adelaide Hospital

    Adelaide, South Australia 5000
    Australia

    Site Not Available

  • Royal Hobart Hospital

    Hobart, Tasmania 7000
    Australia

    Site Not Available

  • Ballarat Base Hospital

    Ballarat Central, Victoria 3350
    Australia

    Site Not Available

  • Box Hill Hospital

    Box Hill, Victoria 3128
    Australia

    Site Not Available

  • Northern Hospital

    Epping, Victoria 3076
    Australia

    Site Not Available

  • St Vincent's Hospital, Melbourne

    Fitzroy, Victoria 3065
    Australia

    Site Not Available

  • Western Health Footscray Hospital

    Footscray, Victoria 3011
    Australia

    Site Not Available

  • Austin Health

    Heidelberg, Victoria 3084
    Australia

    Site Not Available

  • Peter MacCallum Cancer Centre

    Melbourne, Victoria 3000
    Australia

    Site Not Available

  • The Alfred Hospital

    Melbourne, Victoria 3004
    Australia

    Site Not Available

  • The Royal Melbourne Hospital

    Parkville, Victoria 3050
    Australia

    Site Not Available

  • Goulburn Valley Health

    Shepparton, Victoria 3630
    Australia

    Site Not Available

  • Northeast Health, Wangaratta

    Wangaratta, Victoria 3677
    Australia

    Site Not Available

  • Fiona Stanley Hospital

    Murdoch, Western Australia 6150
    Australia

    Site Not Available

  • St John of God Subiaco Hospital

    Subiaco, Western Australia 6008
    Australia

    Site Not Available

  • Auckland City Hospital

    Auckland, 2023
    New Zealand

    Site Not Available

  • North Shore Hospital

    Auckland, 0620
    New Zealand

    Site Not Available

  • Cleveland Clinic

    Cleveland, Ohio 44195
    United States

    Site Not Available

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania 15213
    United States

    Site Not Available

  • The University of Texas MD Anderson Cancer Centre

    Houston, Texas 77030
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.